Metastases, Neoplasm Clinical Trial
Official title:
Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases
Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure. The value of radiomics is evaluated in this perspective.
Sensitivity is low for prediction of long term survival of currently available prognostic scores for brain metastases. First the current clinical models will be optimized with a new prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on CT and MR images. These tumor characteristics may reflect tumor biology and outcome. Therefore it is investigated if radiomics improves prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics for local failure is investigated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00065117 -
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
|
Phase 2 | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Terminated |
NCT00048893 -
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00037869 -
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
|
Phase 3 | |
Completed |
NCT00034918 -
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT01115751 -
A Study in Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
Completed |
NCT00056173 -
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05419518 -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
|
Phase 2 | |
Terminated |
NCT00034697 -
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
|
Phase 2 | |
Completed |
NCT00055471 -
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT00046514 -
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00046527 -
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT00041808 -
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
|
Phase 1/Phase 2 | |
Completed |
NCT00037609 -
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00038038 -
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
|
N/A | |
Completed |
NCT03670992 -
Surgical Treatment of Pancreatic RCC Metastases
|
||
Terminated |
NCT00050336 -
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
|
Phase 3 | |
Recruiting |
NCT03563326 -
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
|
Phase 1 | |
Completed |
NCT00044863 -
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
|
Phase 2 |